Literature DB >> 31342772

Antibiotic Dosing for Critically Ill Adult Patients Receiving Intermittent Hemodialysis, Prolonged Intermittent Renal Replacement Therapy, and Continuous Renal Replacement Therapy: An Update.

Brian M Hoff1, Jenana H Maker2,3, William E Dager3, Brett H Heintz4,5.   

Abstract

Objective: To summarize current antibiotic dosing recommendations in critically ill patients receiving intermittent hemodialysis (IHD), prolonged intermittent renal replacement therapy (PIRRT), and continuous renal replacement therapy (CRRT), including considerations for individualizing therapy. Data Sources: A literature search of PubMed from January 2008 to May 2019 was performed to identify English-language literature in which dosing recommendations were proposed for antibiotics commonly used in critically ill patients receiving IHD, PIRRT, or CRRT. Study Selection and Data Extraction: All pertinent reviews, selected studies, and references were evaluated to ensure appropriateness for inclusion. Data Synthesis: Updated empirical dosing considerations are proposed for antibiotics in critically ill patients receiving IHD, PIRRT, and CRRT with recommendations for individualizing therapy. Relevance to Patient Care and Clinical Practice: This review defines principles for assessing renal function, identifies RRT system properties affecting drug clearance and drug properties affecting clearance during RRT, outlines pharmacokinetic and pharmacodynamic dosing considerations, reviews pertinent updates in the literature, develops updated empirical dosing recommendations, and highlights important factors for individualizing therapy in critically ill patients. Conclusions: Appropriate antimicrobial selection and dosing are vital to improve clinical outcomes. Dosing recommendations should be applied cautiously with efforts to consider local epidemiology and resistance patterns, antibiotic dosing and infusion strategies, renal replacement modalities, patient-specific considerations, severity of illness, residual renal function, comorbidities, and patient response to therapy. Recommendations provided herein are intended to serve as a guide in developing and revising therapy plans individualized to meet a patient's needs.

Entities:  

Keywords:  antibiotic; critical illness; hemodiafiltration; hemodialysis; hemofiltration; pharmacokinetics; renal replacement therapy

Mesh:

Substances:

Year:  2019        PMID: 31342772     DOI: 10.1177/1060028019865873

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  15 in total

1.  Reply to Baud and Houzé, "Should In Vitro and In Vivo Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?"

Authors:  E Wenzler; M Biagi; X Tan; D A Butler
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

2.  Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.

Authors:  Eric Wenzler; David Butler; Xing Tan; Takayuki Katsube; Toshihiro Wajima
Journal:  Clin Pharmacokinet       Date:  2021-11-18       Impact factor: 5.577

3.  A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear).

Authors:  Hussain Allawati; Linda Dallas; Sreejith Nair; Janine Palmer; Shaiju Thaikandy; Colin Hutchison
Journal:  Toxins (Basel)       Date:  2020-05-12       Impact factor: 4.546

4.  Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy.

Authors:  Lauren Andrews; Scott Benken; Xing Tan; Eric Wenzler
Journal:  BMC Nephrol       Date:  2021-01-30       Impact factor: 2.388

Review 5.  Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis.

Authors:  Christo Cimino; Yvonne Burnett; Nikunj Vyas; Anne H Norris
Journal:  Drugs       Date:  2021-02-16       Impact factor: 11.431

Review 6.  Continuous renal replacement therapy and the COVID pandemic.

Authors:  Jacob S Stevens; Juan Carlos Q Velez; Sumit Mohan
Journal:  Semin Dial       Date:  2021-03-11       Impact factor: 2.886

7.  Etiology Analysis and Diagnosis and Treatment Strategy of Traumatic Brain Injury Complicated With Hyponatremia.

Authors:  Jianhua Zhang; Wensheng Dong; Xianghong Dou; Jinjin Wang; Peng Yin; Hui Shi
Journal:  Front Surg       Date:  2022-02-21

8.  Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance.

Authors:  Christina König; Anna Both; Holger Rohde; Stefan Kluge; Otto R Frey; Anka C Röhr; Dominic Wichmann
Journal:  Antibiotics (Basel)       Date:  2021-05-28

Review 9.  Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.

Authors:  Lu Li; Xin Li; Yanzhe Xia; Yanqi Chu; Haili Zhong; Jia Li; Pei Liang; Yishan Bu; Rui Zhao; Yun Liao; Ping Yang; Xiaoyang Lu; Saiping Jiang
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

Review 10.  Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics.

Authors:  Milo Gatti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2021-06-14       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.